CAM2029 is a long-acting octreotide subcutaneous depot designed for easy and convenient self-administration using an autoinjector pen. CAM2029 is approved for treatment of acromegaly in the EU and is pending resubmission in the US.

The ACROINNOVA program, initiated in 2019, includes two Phase 3 studies evaluating CAM2029 for the treatment of acromegaly:

ACROINNOVA 1, a 24-week study, assessed efficacy and safety of CAM2029 compared to placebo with positive results announced in July 2023, published in 2024.¹

Clinicaltrials.gov

ACROINNOVA 2, a 52-week long-term safety and extension study with positive results announced in July 2023² and July 2024³.

Clinicaltrials.gov

CAM2029 is based on Camurus' proprietary FluidCrystal® technology. 

<sup>References
1. Ferone, D., et al. J Clin Endocrinol Metab. Published 8 Oct, 2024.
2. https://www.camurus.com/media/press-releases/2023/camurus-announces-new-phase-3-data-reinforcing-long-term-safety-and-efficacy-of-octreotide-sc-depot-cam2029-in-patients-with-acromegaly/
3. https://www.camurus.com/media/press-releases/2024/camurus-announces-positive-phase-3-results-from-the-acroinnova-2-study-of-octreotide-sc-depot-cam2029-in-acromegaly-patients/</sup>

CAM2029 is a long-acting octreotide subcutaneous depot designed for easy and convenient self-administration using an autoinjector pen. The ongoing Phase 3 study SORENTO evaluates the efficacy and safety of CAM2029 in over 300 patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET). The primary objective is to assess superiority of treatment with CAM2029 compared to current standard of care. Primary endpoint is progression-free survival (PFS).

Clinicaltrials.gov

CAM2029 is based on Camurus' proprietary FluidCrystal® technology. 

CAM2029 is a long-acting octreotide subcutaneous depot designed for easy and convenient self-administration using an autoinjector pen. The POSITANO Phase 2b study, initiated in 2022, assesses efficacy and safety of CAM2029 in over 70 patients with symptomatic polycystic liver disease (PLD). Positive results were announced in June 2025¹. An open extension phase is ongoing.

Clinicaltrials.gov

CAM2029 has Orphan Drug Designation in the US and EU for the treatment of autosomal dominant PLD.

CAM2029 is based on Camurus' proprietary FluidCrystal® technology.

^{1. https://www.camurus.com/media/press-releases/2025/camurus-positano-study-shows-treatment-effects-with-cam2029-in-polycystic-liver-disease-patients/}

CAM2038 is a long-acting buprenorphine subcutaneous depot being developed for the treatment of chronic pain. The product candidate is based on Camurus' proprietary FluidCrystal® technology and is intended for weekly or monthly administration.

CAM2038 has been evaluated in a Phase 2 study in patients with chronic non-cancer pain and opioid dependence, in a 12-week Phase 3 study in opioid-experienced patients with chronic low-back pain, and in a 12-month long-term efficacy and safety study also including patients with other chronic pain conditions. 

CAM4072 is a weekly setmelanotide depot being developed for a range of rare genetic obesity disorders. The product candidate is based on Camurus' proprietary FluidCrystal® technology with the aim to offer patients more convenient dosing with the possibility of improved treatment adherence. Camurus’ license partner Rhythm Pharmaceuticals completed a Phase 3 study in 2023, including patients with Bardet-Biedl’s syndrome previously treated with daily setmelanotide.

CAM2043 is a long-acting subcutaneous treprostinil depot being developed for the treatment of Raynaud’s phenomenon secondary to systemic sclerosis. The product candidate is based on Camurus’ proprietary FluidCrystal® technology for weekly self-administration.

CAM2043 has been evaluated in a Phase 1 study assessing pharmacokinetics, safety and tolerability of once-weekly subcutaneous injections, and in a Phase 2a study in patients with Raynaud’s phenomenon secondary to systemic sclerosis.

CAM4071 is a long-acting formulation of pasireotide based on Camurus’ proprietary FluidCrystal® technology. Pasireotide is currently approved for the treatment of Cushing’s syndrome and acromegaly. 

The product candidate has been evaluated in a Phase 1 study, assessing pharmacokinetics, pharmacodynamics and safety of CAM4071 in healthy volunteers.

CAM2056 is a monthly depot of the GLP-1 receptor agonist semaglutide, in development for the treatment of metabolic diseases and several other potential indications.

CAM2056 is being evaluated in a Phase 1 study to assess pharmacokinetics, pharmacodynamics (including weight loss), tolerability, and safety of CAM2056 compared to weekly semaglutide in overweight or obese participants who are otherwise healthy.

CAM2032 is a long-acting subcutaneous leuprolide depot being developed for the treatment of prostate cancer. The candidate is based on Camurus’ proprietary FluidCrystal® technology for monthly self-administration.

CAM2032 has been evaluated in two Phase 2 studies in patients with prostate cancer. The first study assessing pharmacodynamics (serum testosterone inhibition), pharmacokinetics and safety of subcutaneous (abdominal and buttock) injections. The second study assessing pharmacokinetics, pharmacodynamics, efficacy and safety of repeated doses of CAM2032 versus competitor.

Additional potential indications for CAM2032 include endometriosis and precocious puberty.

CAM2043 is a long-acting subcutaneous treprostinil depot being developed for the treatment of pulmonary arterial hypertension. The product candidate is based on Camurus’ proprietary FluidCrystal® technology for weekly self-administration.

CAM2043 has been evaluated in a Phase 1 study assessing pharmacokinetics, safety and tolerability of once-weekly subcutaneous injections.

CAM2047 is a long-acting subcutaneous granisetron depot in development for treatment of chemotherapy-induced nausea and vomiting (CINV) – a side effect experienced by the majority of cancer patients undergoing chemotherapy. CAM2047 has been evaluated in a completed Phase 1 study.